The Pharmasyntez Group of Companies took part in the leading biopharmaceutical forum, BIOCHINA 2025, which was held in Suzhou. Leading Chinese and foreign businesses in the biotechnology and biopharmaceuticals sectors were brought together in this forum, which covered important topics like cell and gene therapy, monoclonal antibodies, vaccines, synthetic drugs, peptide-based drugs, and nucleic acids.
Vikram Punia, president of Pharmasyntez, expressed his high regard for Russian-Chinese cooperation, which he believes opens new horizons for both countries. The president underlined that China's biopharmaceutical industry has advanced to an impressive degree and is a model for many other countries. In addition to bolstering economic ties, Vikram expressed confidence that cooperation in this area will advance healthcare globally. He pointed out that collaborative efforts can significantly influence the global pharmaceutical industry and encourage the development of novel technologies and solutions that will help people all over the world.
Being a center for innovation and global cooperation in the biopharmaceutical industry, BIOCHINA is distinguished by its emphasis on advanced biotechnologies. This event has become a perfect platform for fostering scientific and commercial ties between Chinese and Russian businesses in the development, registration, and distribution of pharmaceuticals.
Pharmasyntez-Nord actively engaged in the event, holding a series of productive working meetings and participating in discussions on key directions in biopharmaceutical development and Russian-Chinese cooperation.
Mikhail Kvasnikov, the plant's CEO, underlined:
"Being a part of BIOCHINA is a chance to highlight our recent successes and demonstrate our dedication to creating cutting-edge solutions for the healthcare system. We believe that our collaboration with partners and clients will help create breakthrough approaches for sustainable growth and improved quality of life for patients."
The Business Development Department of Pharmasyntez, led by Natalya Malykh, Vice President, is actively establishing and strengthening relationships with Chinese partners by setting up meetings and exchanges with important figures in the biopharmaceutical industry:
"Attending the BIOCHINA exhibition is of immense importance for our company. We are confident that the exchange of knowledge and experience with the international biotechnology community will enhance the quality of our medications and increase the technological sophistication of our product portfolio. The pharmaceutical sector is undergoing revolutionary changes, and as Pharmasyntez, we aim to be at the forefront of this process. Innovative technologies open new horizons and opportunities not only for our company but also for improving the country's healthcare system as a whole."
This strategy emphasizes the value of Russian-Chinese collaboration and how it effects on the advancement of contemporary medical technology and the pharmaceutical industry.
In order to support the goal of improving the health and well-being of people worldwide, BIOCHINA expands the scope of innovation and fortifies cooperation in pharmaceutical technologies.
The BIOCHINA 2025 exhibition and forum took place across 50,000 square meters in five halls, attracting over 10,000 delegates from China and other countries. In order to demonstrate the industry's diversity and inventive potential, participants displayed a broad range of goods and services, such as pharmaceutical equipment, laboratory instruments, technical services, raw materials, reagents, and consumables.